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Section A 
Short Essay Questions 
Total Number of Marks for this section: 90 Marks  
 
This section should be answered in the Answer Booklet provided. 
 
Marks for each question are indicated.  
Suggested Time allocation for Section A: 90 minutes 
 
Question 1 
a) Outline the distribution of magnesium in human body. 
b) Briefly identify the roles of serum magnesium level in current healthcare 
practice. 




a)  Briefly describe how renal function tests can be utilised for the diagnosis and 
monitoring of these common kidney disorders: (i) acute renal failure (acute 
kidney injury), and (ii) chronic renal failure (chronic kidney disease)? 
b)  Comment on the following results for Mrs X’s renal function test. The test was 
order by her doctor after Mrs X complains of worsening symptoms from 
cold/flu. 
• Urea 16 
• Serum Cr 122 
• eGFR 38 
Mrs X is a 68 year-old overweight female (102 kg), who was diagnosed with 
diabetes mellitus over 5 years ago. However, Mrs X has not been taking the 
medication (Metformin) prescribed by her doctor regularly, and relied on 
‘natural therapy’ to manage her condition.  




Discuss the common mechanisms which can cause each of these following 
disturbances. Give examples to illustrate your answers in each scenario. 
• Hyperkalaemia 
• Hypocalcaemia 
 (5 + 5 = 10 Marks) 
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Question 4 
Briefly discuss any THREE of the following biochemistry tests. What information can 
they provide in regard to the health of an individual? Give examples to illustrate your 
answer. 
• NT-proBNP – in cardiac function test 
• Saliva cortisol – in adrenal function test 
• CRP  – in liver function test or cardiac function test 
• Oral glucose challenge test – in pituitary (growth hormone) test 




Discuss any TWO of the following biochemistry tests. What information can they 
provide in regard to the health of an individual? Give examples to illustrate your 
answer. 
• Troponin T 
• HbA1c 
• Bilirubin (serum) 




a)  What can the routine TSH test tell you about the potential health issue(s) of a 
middle age adult? 
b)  Comment on the following results for Mrs Y’s routine screening test, which 
was ordered after she experienced a few incidence of fainting. She is a 46 
year-old female with a family history of high cholesterol (both her parents) and 
diabetes (her mother and her older sister). Mrs Y is a smoker, slightly 
overweight, but has not been diagnosed with any disease or requires any 
regular medication.  
• TSH 7.4 
• T4 (free) 9.1 
 (6 + 7 = 13 Marks) 
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Question 7 
a) List and describe the common causes for variations in the clinical laboratory 
test results. 
b) Explain the properties of an ideal marker to distinguish health and disease 
states in humans. 
(7.5 + 7.5 = 15 Marks) 
 
(Total Marks for Section A: 90 Marks)  
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Case Study Based Questions 
Total Number of Marks for this section: 90 Marks 
 
This section should be answered in the Answer Booklet provided. 
 
Marks for each question are indicated.  




Mr AA is a 62 year-old male, who presents to his GP (Dr X) complaining of severe 
right ankle pain which is not relief by Panadol® (paracetamol) or Nurofen® 
(ibuprofen). Mr AA had a fall 2 days ago when he stepped into a pothole on the 
street, and the pain has worsened overnight. Mr AA has hypertension, high 
cholesterol, type II diabetes mellitus, and chronic renal failure (Baseline Cr ~ 400 
micromol/L).  
The initial physical examination indicates that Mr AA has a swollen right ankle with an 
open wound, an elevated blood pressure (164/97 mmHg), and mild fever (38.2°C). 
The doctor orders an X-ray on Mr AA’s right foot, as well as a few blood tests, which 
include a full electrolyte panel, full blood panel, liver function tests, and HbA1c. The 
results are as follows: 
U&E FBE 
Na 134 Hb 168 
K 4.8 RCC 5.9 
Cl 90 Hct 45% 
Urea 20.9 MCV 76 
Cr 839 WCC 15.2 
eGFR 5 Platelet 496 
Ca (total) 2.29 Others 
Mg 0.71 Total protein 80 
Phosphate 1.55 Alb 37 
LFT CRP 87 
ALP 166 HbA1c 11.2% 
ALT 22   
GGT 42   
Bilirubin 9   
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Questions 
a) What do the serum U&E results indicate/ suggest? Discuss whether this 
indication matches with Mr AA’s current clinical presentation. 
(8 Marks) 
 
b) What are the likely reasons that can contribute to this Mr AA’s condition? 
(5 Marks) 
 
c) What do the other laboratory results (LFT, FBE, others) indicate/ suggest? 
Discuss whether this indication(s) matches with Mr AA’s clinical presentation 




d) What other biochemistry test(s) would you recommend to help confirm or 
exclude the potential diagnosis identified in Question A and Question C? 
Justify your recommendation and explain what finding will be the most useful. 
(6 Marks) 
 
e) During and after an appropriate treatment is introduced, what biochemistry 
test(s) would you recommend to monitor Mr AA’s progression? Justify your 
recommendation and explain how this test(s) should be used. 
(6 Marks) 
(Total marks for Question 8: 33 marks) 
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Question 9 
Case 2 
Mrs BB is a 34 year-old female. She is overweight (93 kg, 175 cm tall), and is a 
current smoker. She has regular medical check-ups with her GP to manage her 
migraine. Besides migraine, Mrs BB is also diagnosed with type 2 diabetes and 
polycystic ovary syndrome. She is currently being treated with gliclazide (for 
diabetes), and propranolol (for migraine). 
Mrs BB plans to get pregnant and starts a family with her partner. However, she 
wants to get her diabetes under control and hopes to stop taking her diabetes 
medication during her pregnancy. 
Note: (i) gliclazide is a sulfonylurea which stimulates insulin secretion from functional 
pancreatic β-cells; (ii) propranolol is a non-selective beta-blocker which competitively 
inhibits the effect of adrenaline on sympathetic nerve system. 













Hb 98   129  108 
RCC 3.8   4.5  3.9 
Hct 40     43 
MCV 105     110 
Plt 396   233  294 
WCC 8.9   17.6  4.1 
Neutrophil       
Lymphocyte       
Monocyte       
Na  141  151 136 143 
K  3.9  4.8 3.2 4.1 
Cl  101  112 92 104 
Urea  4.3  12.5 6.1 7.4 
Cr  59  94 72 81 
eGFR  >90  59 80 70 
Total cholesterol   6.8   6.1 
LDL   4.6   4.2 
HDL   1.0   0.8 
TG   2.6   2.4 
BGL (fasting) 5.8  8.1  6.8 5.9 
        (random)  9.4  12.4   
HbA1c  8.5   8.9 6.8 
CRP    35   
TSH     2.4  
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Questions 
a) What do Mrs BB’s biochemistry results on 15-May-2016 indicate/ suggest? 
Explain your answer. 
(5 Marks) 
 
b) Considering the medical history of Mrs BB for the past 4 years, discuss the 
control of Mrs BB’s diabetes. 
(8 Marks) 
 
c) Considering the medical history of Mrs BB for the past 4 years, discuss the 
control of Mrs BB’s cholesterol management. 
(8 Marks) 
 
d) Considering that Mrs BB’s is planning to become pregnant, what monitoring 
and/or additional biochemistry test(s) would you recommend? Justify your 
choice with reference to Mrs BB’s clinical presentation and her existing 
laboratory test results.  
(8 Marks) 
 (Total marks for Question 9: 29 marks)  
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Question 10 
Case 3 
Mr CC is a 38 year-old man who was brought to the hospital after being found semi-
conscious on the street by police. Mr CC was accompanied by two of his friends 
when they were picked up by the police. They described that they have been drinking 
heavily for a few days, but did not eat or drink much water. According to his friends, 
Mr CC does not have any known medical disorder, and is not taking any regular 
medication regularly. 
During the examination, Mr CC complained about abdominal pain and vomited about 
a minute later. His blood pressure is low (104/68 mmHg) but with a very rapid heart 
rate (124 bpm). Blood samples were taken, and the results were as follows: 
 
U&E FBE 
Na 127 Hb 164 
K 4.9 RCC 4.7 
Cl 86 Hct 58 
Urea 11.4 WCC 10.8 
Cr 183 LFT 
eGFR 37 ALT 75 
Anion gap 23 AST 122 
ABG ALP 154 
pH 7.28 GGT 266 
pCO2 27 Others 
pO2 94 BGL (random) 2.9 
HCO3 35 CRP 72 
SatO2 98% Troponin T -ve 
 
Questions 
a) What do the results in his arterial blood gas (ABG) show? Explain why Mr CC 
might have developed this condition? 
(10 Marks) 
 
b) Based on your answer in Question 10(a), briefly outline any additional 
biochemistry test(s) and/or follow-up monitoring you would recommend for 
Mr CC.  
(6 Marks) 
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d) What do the other biochemistry tests (U&E, FBE, and others) results indicate/ 
suggest? Explain your answer. 
(5 Marks) 
(Total marks in Question 10: 28 marks) 
 
(END OF EXAM PAPER)  
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Reference ranges for regular lab tests used in this particular 
laboratory 
 
Urea and electrolytes (U&E) 
Na 135.0-145.0 mmol/L 
K 3.50-4.50 mmol/L (plasma) 3.8-4.9 mmol/L (serum) 
Cl 95-110 mmol/L 
Urea 3.8-8.0 mmol/L 
Creatinine 60-100 micromol/L 
eGFR > 90 mL/min/1.73 m2  
Osmolality (serum) 275-295 mOsm/kg 
Anion gap 13-17 mEq/L 
 
Calcium, magnesium and phosphate (CMP) 
Ca (total) 2.1-2.6 mmol/L 
Ca (ionised) 1.16-1.3 mmol/L 
PO43-  0.8-1.5 mmol/L 
Mg 0.8-1.0 mmol/L 
 
Arterial blood gas (ABG) 
pH 7.35-7.45 
pO2 80-110 mmHg 
pCO2 35-45 mmHg 
Bicarbonate (HCO3-) 22-33 mmol/L 
 
Full blood examination (FBE) 
Hb 140-174 (male); 120-160 (female) g/L 
RCC 4.50-5.50 (male); 4.0-5.0 (female) x10 12 /L 
Haematocrit 0.42-0.52 or 42-52 % (male);  
 0.36-0.48 or 36-48% (female) 
MCV 80.0-100.0 fL 
RDW 11.5-14.5 % 
Platelets 150-450 (x10 9 /L) 
WCC 4.0-11.0 (x10 9 /L) 
Neutrophil 40-80%; or2.0-7.5 (x10 9 /L) 
Lymphocytes 20-40%; or 1.5-4.0 (x10 9 /L) 
Monocytes 2-10%; or 0.2-0.8 (x10 9 /L) 
Eosinophils 1-6%; or 0.0-0.4 (x10 9 /L) 
Basophils <2%; or 0.0-0.1 (x10 9 /L) 
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Liver function test (LFT) 
ALT <30 U/L 
AST <40 U/L 
ALP 30-100 U/L 
GGT <30 U/L (female); <50 U/L (male) 
Bilirubin (total) <20 micromol/L 
Bilirubin (conjugated) <4.0 micromol/L 
Albumin 32-45 g/L 
Total protein 63-80 g/L 
Pancreatic lipase 8 – 78 U/L 
 
Thyroid function test (TFT) 
TSH 0.4-5.0 mU/L 
T4 (free) 10-25 pmol/L 
T3 (free) 3.0-6.5 pmol/L 
 
Carbohydrate metabolism 
BSL (random) 3.0-7.7 mmol/L 
BSL (fasting) 3.0-5.5 mmol/L 
HbA1c (non-DM) 4.3-5.7% (NGSP); 23-39 mmol/mol (IFCC) 
HbA1c (DM) therapeutic target <7% * 
 
Fasting lipid biochemistry 
Total cholesterol <5.5 mmol/L 
LDL 2-3.4 mmol/L 
HDL >1 mmol/L 
Non-HDL cholesterol <2.5 mmol/L 
TG <1.7 mmol/L 
 
Others 
Troponin T <0.01 µg/L 
CRP <3 mg/L 
D-dimer <500 µg/L 
BNP <20 nmol/L 
 
 
 
